News Headlines

1. WuXi Biologics And Bayer Enter Into An Acquisition Agreement On A Drug Product Plant In Germany 1/17/2020

   WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Bayer jointly announced an acquisition agreement that WuXi Biologics Germany GmbH will take over the operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building.

2. Food And Pharma Equipment Leader Bosch Packaging Technology Is Now Syntegon 1/16/2020

   Syntegon Technology is the new name among the market leaders in the processing and packaging industry.

3. Eli Lilly To Add Eczema Drug With $1.1B Deal For Dermira 1/11/2020

   Lilly will pay $18.75 per Dermira share, or a 2.2% premium to Dermira’s last closing price. It said the price represented a premium of about 86% to Dermira’s 60-day volume-weighted average trading price including Friday’s closing price.

4. Consulting And Services Firm ZS Opens Three New Offices: Seattle, Washington, DC And Cambridge, UK 1/2/2020

   In a move to continue expanding our firm’s global presence—and to increase our proximity to key clients—ZS is excited to announce that three new offices will open their doors on Jan. 2, 2020: Seattle, Washington, D.C., and Cambridge, U.K.

5. Astellas Strengthens Immuno-Oncology Pipeline With Acquisition Of Xyphos Biosciences, Inc. 12/26/2019

   Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Xyphos Biosciences, Inc. (CEO: James Knighton, "Xyphos") today announced that Astellas has acquired Xyphos.

6. TOWA PHARMACEUTICAL CO., LTD. Reaches An Agreement With ESTEVE To Acquire ESTEVE’s Generic Division, Pensa Investments 12/23/2019

   TOWA PHARMACEUTICAL CO.,LTD. (Osaka, Japan) (TOWA) and ESTEVE (Barcelona, Spain) announced today that TOWA will acquire 100% ownership of Pensa Investments, S.L. (Pensa), the generics division of the Spanish pharmaceutical company ESTEVE.

7. Tessa Therapeutics To Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility In Singapore In 2020 12/19/2019

   Tessa Therapeutics (Tessa), a clinical-stage cell therapy company focused on the development of innovative cell therapies to treat cancer, today announced plans to open a 90,000 square foot commercial-scale cell therapy manufacturing facility in Singapore by end-2020, which will be one of the leading commercial-scale cell therapy manufacturing facilities in Asia.

8. CDMO Alcami Announces Plans To Add Capacity For Sterile Drug Product Development And Manufacturing 12/18/2019

   Alcami, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biologics industries, plans to expand the company’s current operations in North Charleston, South Carolina.

9. Symbiosis Invests £1.5M In UK Facility Expansion 12/17/2019

   Fast-growing specialist sterile manufacturing and Contract Manufacturing Organisation (CMO) Symbiosis Pharmaceutical Services (Symbiosis), has expanded its sterile biologics manufacturing facility in Scotland, UK by 25%.

10. Recipharm Partners With Aptahem For Formulation Of Apta-1 Drug Candidate 12/17/2019

    Recipharm, the contract development and manufacturing organisation (CDMO) has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate.